Cargando…
ELOVL2-AS1 suppresses tamoxifen resistance by sponging miR-1233-3p in breast cancer
Tamoxifen (Tam) has long been a top treatment option for breast cancer patients, but the challenge of eliminating cancer recurrence remains. Here, we identify a signalling pathway involving ELOVL2, ELOVL2-AS1, and miR-1233-3p, which contributes to drug resistance in Tam-resistant (TamR) breast cance...
Autores principales: | Kim, Hyeon Woo, Baek, Minjae, Jung, Sanghyun, Jang, Siyeon, Lee, Hyeonjin, Yang, Seung-Hoon, Kwak, Beom Seok, Kim, Sun Jung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10621244/ https://www.ncbi.nlm.nih.gov/pubmed/37908128 http://dx.doi.org/10.1080/15592294.2023.2276384 |
Ejemplares similares
-
MicroRNAs in Renal Cell Carcinoma: Diagnostic Implications of Serum miR-1233 Levels
por: Wulfken, Lena M., et al.
Publicado: (2011) -
Downregulation of Choline Kinase-Alpha Enhances Autophagy in Tamoxifen-Resistant Breast Cancer Cells
por: Kim, Hoe Suk, et al.
Publicado: (2015) -
Glioblastoma Multiforme Tumors in Women Have a Lower Expression of Fatty Acid Elongases ELOVL2, ELOVL5, ELOVL6, and ELOVL7 than in Men
por: Korbecki, Jan, et al.
Publicado: (2022) -
Matrix Metalloproteinase-1 (MMP1) Upregulation through Promoter Hypomethylation Enhances Tamoxifen Resistance in Breast Cancer
por: Kim, Hyeon Woo, et al.
Publicado: (2022) -
Plasmatic miR-210, miR-221 and miR-1233 profile: potential liquid biopsies candidates for renal cell carcinoma
por: Dias, Francisca, et al.
Publicado: (2017)